Share This Author
Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.
- H. Wang, Z. Liao, +7 authors D. Gomez
- Annals of oncology : official journal of the…
- 1 May 2013
Beta-blocker use is associated with improved DMFS, DFS, and OS in this large cohort of NSCLC patients and future prospective trials can validate these retrospective findings and determine whether the length and timing of beta-blockers use influence survival outcomes. Expand
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
PEP02 apparently modified the PK parameters of irinotecan and SN-38 by liposome encapsulation, and the MTD of PEP02 monotherapy at 3-week interval is 120 mg/m2, which will be the recommended dose for future studies. Expand
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
This oxaliplatin-containing regimen is effective in the treatment of advanced gastric cancer and Except for neurotoxicity that often develops after prolonged use of oxali Platin, the regimen is well tolerated. Expand
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
Addition of cetuximab did not significantly improve the ORR of GEMOX chemotherapy in ABTC, although a trend of PFS improvement was observed, and the trend of improvement did not correlate with KRAS mutation status. Expand
Radiation Therapy Oncology Group (RTOG) Protocol 0915: A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I…
In the largest study of its kind to date, predictive models constructed using FDG-PET intensity and shape features significantly correlated to LF, RF, and DM in the test cohort and on LOOCV, and with LF with an independent population are constructed. Expand
Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?
- A. Cheng, Y. Chen, +7 authors H. Tien
- Journal of clinical oncology : official journal…
- 1 June 1989
Peripheral T-cell lymphoma follows the general grading concept proposed in WF classification; within a given intermediate or high grade, PTCL and DBCL respond comparably to treatment; the intensity of induction chemotherapy has a crucial impact on the outcome of P TCL patients; and with a few exceptions, the clinical and laboratory features are comparable. Expand
A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patients—An…
Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma.
- J. Wang, B. Myles, +8 authors S. H. Lin
- Diseases of the esophagus : official journal of…
- 1 February 2014
In esophageal cancer patients treated with CRT, obesity is not predictive of poorer disease outcomes or operative morbidities; instead, data suggest it may be associated with decreased risk of acute chemotherapy- and radiotherapy-related treatment toxicities. Expand
Results of a Phase II Randomized Trial of Proton Beam Therapy vs Intensity Modulated Radiation Therapy in Esophageal Cancer
Effects of indomethacin on lymphokine-activated killer cell activities in cancer patients.
- T. Chao, C. Ting, M. Yeh, J. Chang, C. Wang, T. Chu
- Tumour biology : the journal of the International…
Results indicated that indomethacin inhibited generation of LAK cell activity in cancer patients with a poor performance status or with distant metastatic disease, who normally would be the subjects of adoptive immunotherapy. Expand